VEGFA and osteosarcoma: Sunitinib is a small molecule receptor tyrosine kinase (RTK) inhibitor that blocks signaling of multiple RTKs, including vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptors (9), with pre-clinical evidence of activity in metastasizing osteosarcomas (10).